Review for family doctors: cannabis helps chronic and nerve pain but carries addiction risk and psychotropic side effects | Research

The takeaway

A review for family physicians found clinical evidence supporting cannabis for chronic and neuropathic pain, while noting synergistic cannabinoid-opioid interactions could potentially reduce drug-seeking behavior.

Read this if you want a balanced overview of medical cannabis from a primary care perspective.

Cannabinoid-opioid synergy could produce opioid-sparing effects

What the researchers found

The review provided a practical update for family physicians on medical cannabis, covering several key points.

Clinical trials demonstrated benefits for alleviating chronic and neuropathic pain, though significant psychotropic and physical side effects accompanied use. The addiction potential was acknowledged.

Recent laboratory data highlighted synergistic interactions between cannabinoid and opioid receptors. These interactions had two important implications: potential reduction in drug-seeking behavior and opioid-sparing effects (lower opioid doses needed when combined with cannabinoids).

The legal landscape was changing, with certain US states permitting medical marijuana, and family physicians needed practical knowledge about the pros, cons, legal implications, and future developments.

Why it matters

As the front line of patient care, family physicians needed balanced, practical information about medical cannabis to counsel patients appropriately in a changing legal landscape.

The numbers in context

The review covered clinical trial evidence for chronic and neuropathic pain without reporting specific pooled effect sizes.

How the study worked

Narrative review for the Journal of the American Board of Family Medicine, synthesizing clinical trial evidence, pharmacology, and sociological context of medical cannabis for primary care physicians.

What this study cannot tell us

Narrative review for a clinical audience, not a systematic evidence synthesis. The legal and regulatory landscape described was specific to 2011 and has changed substantially.

How to read the evidence

Clinical narrative review synthesizing available evidence for a primary care audience.

When this study was published

Published in 2011. The medical cannabis landscape, legal framework, and evidence base have changed dramatically since.

The bigger picture

The cannabinoid-opioid synergy findings were particularly relevant given the emerging opioid crisis, suggesting cannabis might reduce reliance on opioid painkillers.

Questions still open

Can cannabis-opioid combinations safely reduce opioid prescribing? How should family physicians counsel patients about medical cannabis in states where it is legal?

Common questions

What does the evidence say about cannabis for pain?

Clinical trials supported cannabis for chronic and neuropathic pain, with the potential bonus of cannabinoid-opioid synergy that could reduce opioid doses needed. However, psychotropic side effects and addiction potential were also documented.

Could cannabis reduce the need for opioid painkillers?

Laboratory data showed synergistic interactions between cannabinoid and opioid receptors, suggesting combination therapy could achieve pain relief with lower opioid doses. Clinical evidence for this approach was still developing.

Read the original research

Cannabis and its derivatives: review of medical use.

Journal of the American Board of Family Medicine : JABFM, 24(4), 452-62

View on PubMed ↗Publisher’s paper ↗

Citation

Leung, Lawrence. (2011). Cannabis and its derivatives: review of medical use.. Journal of the American Board of Family Medicine : JABFM, 24(4), 452-62. https://doi.org/10.3122/jabfm.2011.04.100280